Nikolova Lab
The Nikolova Lab focuses on developing and testing novel diagnostics for heart failure and heart transplant recipients. This includes gene expression profiling assays to identify immune checkpoint inhibitor-related cardiotoxicity and cardio-protective strategies for patients with a genetic signature of toxicity.
Personal Statement
During her cardiology training, Dr. Nikolova obtained her PhD in biomedical sciences, which defined her research focus on developing and testing novel diagnostics for patients with heart failure and heart transplant recipients. Drawing on the similarities in the immunological signatures of cardiac allograft cellular rejection and immune checkpoint inhibitors-associated cardiac toxicity, she has broadened her clinical and research interests to include the field of cardio-oncology.
Andriana Nikolova
Breakthrough Research
Our group was the first to define the role of cardiac Bridging Integrator 1 (cBIN1) as a key regulator of myocardial remodeling. We have spearheaded translational pilot studies applying this biomarker to a cohort of patients with heart failure with preserved ejection fraction (HFpEF) and cardiac allograft rejection.
Publications
Learn more about the recent research publications from the Nikolova Lab.
Job Opportunities
We are actively recruiting students and postdocs to be our colleagues and expand lab knowledge and expertise to make important breakthroughs.
Collaborations
The Nikolova Lab collaborates with a wide range of investigators within Cedars-Sinai and institutions around the world.